CSE Bulletin: Fundamental Change - Glenbriar Technologies Inc./Love Pharma Inc.

Le 29 septembreSeptember 2021) Love Pharma Inc., the issuer resulting from a Fundamental Change of Glenbriar Technologies Inc. (GTI.X), has been approved for listing.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

Love Pharma Inc., is a specialized health and wellness company offering pharmaceutical and therapeutic products with proven technologies for which it has the exclusive rights to produce, package and sell thoughout Europe, North America and the United Kingdom. Many of the products are market-ready, with proven history of significant sales. The Company is focused on the global sexual wellness and enhancement market.

_________________________________

Love Pharma Inc., l'émetteur résultant d'un changement fondamental de Glenbriar Technologies Inc. (GTI.X), a été approuvé pour inscription.

Les documents de cotation et d'information seront disponibles sur www.thecse.com à la date de négociation.

Love Pharma Inc. est une société spécialisée dans la santé et le bien-être offrant des produits pharmaceutiques et thérapeutiques dotés de technologies éprouvées pour lesquelles elle détient les droits exclusifs de production, d'emballage et de vente en Europe, en Amérique du Nord et au Royaume-Uni. De nombreux produits sont prêts à être commercialisés, avec des antécédents avérés de ventes importantes. La Société se concentre sur le marché mondial du bien-être et de l'amélioration sexuelle.

Issuer/Émetteur: Love Pharma Inc.
Security Type/Titre:

Common Shares/Actions ordinaires

Symbol(s)/Symbole(s): LUV
Number of securities issued and outstanding/ Titres émis et en circulation: 314 919 945
Number of Securities reserved for issuance/ Titres réservés pour émission: 73 626 130
CSE Sector/Catégorie: Life Sciences/Sciences Biologiques
CUSIP : 547153 10 6
ISIN : CA 547153 10 6 4
Old/Vieux CUSIP& ISIN: 377904107/CA3779041076
Boardlot/Quotité: 1000
Consolidation: 1 New for 2 Old /1 nouveau pour 2 ancien
Trading Currency/Monnaie de négociation: CDN$/$CDN
Trading Date/Date de negociation: Le 30 septembre/September 2021
Other Exchanges/Autres marches: N/A
Fiscal Year end /Clôture de l'exercice financier: Le 30 septembre/September
Transfer Agent/Agent des transferts: Odyssey Trust Company

 

The Exchange is accepting Market Maker applications for LUV. Please email: Trading@theCSE.com

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com

Pour toute question, pour obtenir de l'information supplémentaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel à l'adresse: Listings@thecse.com

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Invion Limited

Invion Doses First Patient in Phase I/II Non-Melanoma Skin Cancer Trial

Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to announce the dosing of the first patient in its Phase I/II non- melanoma skin cancer (NMSC) trial conducted at Veracity Clinical Research (Veracity) in Brisbane.

Keep reading...Show less
BPH Global

Seaweed Extraction of Critical Minerals R&D

BPH Global (BP8:AU) has announced Seaweed Extraction of Critical Minerals R&D

Download the PDF here.

Resonance Health Ltd

Resonance Contracted by Major Global Pharma Company for Clinical Drug Trial Worth $13.775 Million over 24 Months

Resonance Health Ltd (ASX: RHT) (Resonance or the Company) advises that it has been contracted by Sun Pharmaceutical Industries Limited, an international, publicly listed pharmaceutical company with global operations (Customer) to be the local Australian sponsor, and to provide clinical research organisation (CRO) services, trial site services, and imaging analysis services (collectively, Services), for their clinical trial in Australia of a new drug compound (Clinical Trial).

Keep reading...Show less
  Island Pharmaceuticals

ISLA-101 Phase 2a/b PROTECT Clinical Trial Progress Update

Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress on its ISLA-101 Phase 2a/b clinical trial in dengue fever.

Keep reading...Show less
Amplia Therapeutics

Interim Data from Accent Pancreatic Cancer Trial Supports Continuation of Trial

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to report the interim data analysis from the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial). The trial is investigating the combination of the Company’s best-in-class FAK inhibitor narmafotinib with the standard-of-care chemotherapy regimen of gemcitabine and Abraxane®. Data cut-off for the interim analysis is 27 September 2024.

Keep reading...Show less

Latest Press Releases

Related News

×